Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

NCT05088057 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer (TNBC)

Interventions

DRUG: Camrelizumab
DRUG: Doxorubicin
DRUG: Cyclophosphamide
DRUG: Docetaxel

Sponsor

Aiping Shi